COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,082 Articles (22,658 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 2218: Articles 22171-22180  | Next

Initial Model for USA CoVID-19 Resurgence
Eng, G.
10.1101/2020.09.16.20196063 — Posted: 2020-09-21
Impact of false negative results of RT-PCR test for SARS-CoV-2 in COVID-19 case count as applied to Mexico
Nunez, I. J., Belaunzaran-Zamudio, P. F., Caro-Vega, Y.
10.1101/2020.09.17.20197038 — Posted: 2020-09-21
SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism
Shi, M., Wang, L., Fontana, P., Vora, S., Zhang, Y., Fu, T.-M., Lieberman, J., Wu, H.
10.1101/2020.09.18.302901 — Posted: 2020-09-20 Discussion: Onsite | Offsite
Rapid transition to distance learning due to COVID-19: Perceptions of postgraduate dental learners and instructors
Amir Rad, F., Otaki, F., baqain, Z., Zary, N., Al-Halabi, M.
10.1101/2020.09.19.20197830 — Posted: 2020-09-20
The Effects of Indias COVID-19 Lockdown on Critical Non-COVID Health Care and Outcomes
Jain, R., Dupas, P.
10.1101/2020.09.19.20196915 — Posted: 2020-09-20
SARS-CoV-2 PCR cycle threshold at hospital admission associated with Patient Mortality
Choudhuri, J., Carter, J., Nelson, R., Skalina, K., Osterbur-Badhey, M., Johnson, A., Goldstein, D. Y., Paroder, M., Szymanski, J.
10.1101/2020.09.16.20195941 — Posted: 2020-09-20 Discussion: Onsite | Offsite
Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays
Belda, F., Cherenzia, R., Crowley, M.
10.1101/2020.09.08.20190256 — Posted: 2020-09-20
SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic.
Favara, D. M., McAdam, K., Cooke, A., Bordessa-Kelly, A., Budriunaite, I., Bossingham, S., Houghton, S., Doffinger, R., Ainsworth, N., Corrie, P.
10.1101/2020.09.18.20197590 — Posted: 2020-09-20
Suppression of COVID-19 infection by isolation time control based on the SIR model and an analogy from nuclear fusion research
Mitarai, O., Yanagi, N.
10.1101/2020.09.18.20197723 — Posted: 2020-09-20
Antisense oligonucleotides target a nearly invariant structural element from the SARS-CoV-2 genome and drive RNA degradation
Lulla, V., Wandel, M. P., Bandyra, K. J., Dendooven, T., Yang, X., Doyle, N., Oerum, S., O'Rourke, S., Randow, F., Maier, H. J., Scott, W., Ding, Y., Firth, A., Bloznelyte, K., Luisi, B.
10.1101/2020.09.18.304139 — Posted: 2020-09-19 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).